Orchid Pharma Limited — Important, 03-05-2025: Updates

Orchid Pharma has announced a board meeting to discuss the financial results for the quarter and half-year. The National Company Law Tribunal approved the merger with parent Dhanuka Laboratories, expected to boost sales to Rs.1400-1500 Cr and EBITDA to Rs.200-250 Cr. The consolidation targets improved competitiveness, cost efficiencies, and stronger management focus, positioning the combined entity for enhanced shareholder value through operational synergies. Discussions with unsecured creditors and shareholders are underway to advance the merger process.